Utah has become the first U.S. state to launch a pilot program allowing an autonomous AI system to handle routine prescription renewals for chronic condition medications. Partnering with health-tech startup Doctronic under the state’s AI regulatory sandbox, the initiative aims to improve medication adherence, reduce delays, and ease clinician burdens while maintaining pharmacist oversight and human escalation protocols.
Glimpse:
The program, quietly launched in late 2025 and formally announced January 6, 2026, enables patients to request refills via Doctronic’s AI platform anytime. Limited to ~190 common non-controlled chronic drugs (e.g., blood pressure, diabetes meds; excluding opioids/ADHD), it uses patient history and clinical questions for approvals. The 12-month pilot tracks safety, adherence, access, satisfaction, efficiency, and costs potentially informing national AI healthcare policies
Utah is breaking new ground in healthcare automation with the nation’s first state-approved pilot allowing artificial intelligence to autonomously renew prescriptions for chronic conditions. The Utah Department of Commerce’s Office of Artificial Intelligence Policy (OAIP) partnered with Doctronic an AI-native telehealth platform to deploy this system within Utah’s regulatory sandbox framework.
Patients access a dedicated webpage, verify Utah residency (via ID/selfie), and interact with the AI chatbot. It pulls prescription history, lists eligible refills, asks clinical questions (mirroring physician protocols), and if safe authorizes renewal for pharmacist fulfillment. Cases with uncertainty escalate to human physicians.
Scope & Safeguards:
- Covers ~190 common medications for chronic issues (cardiometabolic, birth control, SSRIs).
- Excludes controlled substances, pain meds, ADHD drugs, injectables.
- Initial 250 refills per drug class require physician review.
- Pharmacists retain final processing authority.
- $4 service fee for automated refills.
The pilot addresses medication nonadherence a driver of >$100 billion annual avoidable costs and ~80% of medication-related activity. By automating low-risk refills, it frees clinicians for complex care while ensuring 24/7 access.
Metrics Tracked: Refill timeliness/adherence, patient access/satisfaction, safety, workflow efficiency, costs. Results will be public, potentially guiding federal policy (e.g., AI Action Plan sandboxes).
Doctronic co-founders Matt Pavelle and Adam Oskowitz, MD, emphasize: AI matches physician plans in 99.2% of tested cases, with guardrails for safety.
Critics (e.g., AMA) warn of risks like missed nuances or manipulation, but proponents see it as a scalable model for physician shortages.
Utah’s sandbox pioneered for AI testing positions the state as a leader, with interest from Arizona, Texas, Missouri.
“This partnership enables patients, pharmacists, and physicians to work together more efficiently. We hope other states follow Utah’s lead.”
By
HB Team
Related News
